These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36752579)

  • 61. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis.
    Hoffmann M; Hayoz S; Özdemir BC
    Biology (Basel); 2022 Mar; 11(3):. PubMed ID: 35336796
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
    Jacques SK; McKeown J; Grover P; Johnson DB; Zaremba A; Dimitriou F; Weiser R; Farid M; Namikawa K; Sullivan RJ; Rutkowski P; Lebbe C; Hamid O; Zager JS; Michielin O; Neyns B; Nakamura Y; Robert C; Mehnert J; Ascierto PA; Bhave P; Park B; Zimmer L; Mangana J; Mooradian M; Placzke J; Allayous C; Glitza Oliva IC; Mehmi I; Depalo D; Wicky A; Schwarze JK; Roy S; Boatwright C; Vanella V; Long GV; Menzies AM; Lo SN; Carlino MS
    Eur J Cancer; 2024 Mar; 199():113563. PubMed ID: 38278007
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
    Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
    Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adjuvant Therapy of Melanoma.
    Tarhini AA
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):73-84. PubMed ID: 33759774
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study.
    Grotz TE; Kottschade L; Pavey ES; Markovic SN; Jakub JW
    Am J Clin Oncol; 2014 Oct; 37(5):467-72. PubMed ID: 23428946
    [TBL] [Abstract][Full Text] [Related]  

  • 68. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
    Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.
    Tetzlaff MT; Adhikari C; Lo S; Rawson RV; Amaria RN; Menzies AM; Wilmott JS; Ferguson PM; Ross MI; Spillane AJ; Vu KA; Ma J; Ning J; Haydu LE; Saw RPM; Wargo JA; Tawbi HA; Gershenwald JE; Long GV; Davies MA; Scolyer RA
    Ann Oncol; 2020 Nov; 31(11):1569-1579. PubMed ID: 32739408
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
    Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
    Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
    Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
    J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
    [No Abstract]   [Full Text] [Related]  

  • 72. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.
    Cavalieri S; Di Guardo L; Cimminiello C; Bono A; Tolomio E; Colombetti A; Valeri B; Di Tolla G; de Braud F; Del Vecchio M
    Tumori; 2016 Oct; 102(5):501-507. PubMed ID: 27470608
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
    Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
    Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
    N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Adjuvant nodal field radiation in resected Stage III melanoma: A single-centre retrospective study in Christchurch, New Zealand.
    Leong TW; McCook G; Frampton CM; Robinson BA; James ML
    J Med Imaging Radiat Oncol; 2022 Oct; 66(7):1003-1013. PubMed ID: 35642730
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
    Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
    Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety of pembrolizumab for resected stage III melanoma.
    Pham F; Dalle S
    Expert Opin Drug Saf; 2020 Oct; 19(10):1221-1227. PubMed ID: 32799585
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma.
    Rutkowski P; Czarnecka AM
    Expert Rev Anticancer Ther; 2023; 23(9):897-902. PubMed ID: 37573515
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety.
    Nebhan CA; Johnson DB
    Expert Rev Anticancer Ther; 2021 Jun; 21(6):583-590. PubMed ID: 33504219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.